Studies have shown that statin, a representative treatment for dyslipidemia, reduces the risk of ischemic stroke in patients with cerebral hemorrhage.
Recently, as studies that show that statins reduce the risk of stroke are continuously accumulating, there is a possibility that they will be established as a new treatment option.
The results of a study on the association between statin use and the risk of stroke recurrence after intracerebral hemorrhage conducted by researchers including David Geist of the Department of Neurology at Odense University Hospital in Denmark were published in the international journal Neurology on the 30th (doi.org/10.1212/WNL.0000000000207792).
Studies have shown that statins, a treatment for dyslipidemia, reduce the risk of ischemic stroke recurrence.
Statins, which lower LDL-C and triglycerides, which are referred to as bad cholesterol, are administered to prevent major cardiovascular diseases such as coronary artery disease.
Risk factors for stroke include hypertension, diabetes, heart disease, transient ischemia as well as dyslipidemia.
The researchers entered a cohort analysis to determine whether statin treatment of survivors of cerebral hemorrhage (ICH) had an impact on future hemorrhagic and ischemic stroke (IS).
To determine whether the incidence of stroke, IS, or recurrent ICH differs by statin use or not in 15,151 people who were diagnosed with first ICH between January 2003 and December 2021 and survived 30 days or longer enrolled in the Danish Stroke Registry. The average follow-up was 3.3 years.
Of these, 1959 patients with stroke were matched with 7400 controls, 1073 IS patients were matched with 4035 controls, and 984 patients with recurrent ICH were matched with 3755 controls.
When the incidence of all strokes, IS, and recurrent ICH related to statin exposure was calculated using conditional logistic regression analysis, the incidence of all types of stroke in the statin exposure group was 38.6%, which was lower than that of the control group (41.1%) (aOR 0.88).
Subsequently, a risk reduction of about 21% was observed with the incidence of IS at 39.8% and the control group at 41.8%, but no risk reduction was observed for recurrent ICH (39.1% vs. 40.8%).
The research team said, “It was confirmed that administering statins to patients who suffered cerebral hemorrhage mainly lowered the risk of IS. concluded.
2023-08-31 02:58:38
#Effects #statins #patients #cerebral #hemorrhage #Ischemic #stroke #recurrence
